Physician profile
Randi M Rothstein
NPI 1437233863
$1,423.00
in general payments reported to CMS, 2019-2025
22 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $152 · 2021: $37.50 · 2022: $126 · 2023: $292 · 2024: $272 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.46 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $226.18 | 2019-2022 | |
| Astellas Pharma US INC | $148.44 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $139.69 | 2023-2025 | Myfembree |
| Organon LLC | $139.60 | 2023-2025 | Nexplanon, Jada System |
| Abbvie INC. | $124.41 | 2019-2020 | |
| Pfizer INC. | $123.54 | 2020-2024 | |
| Hologic Sales and Service, LLC | $111.56 | 2020-2023 | Fluent Fluid Management System, Myosure Tissue Removal Device |
| Millicent US INC | $59.09 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $50.35 | 2022-2023 | |
| Aspira Women'S Health INC | $37.50 | 2021 | |
| Amag Pharmaceuticals, INC. | $35.17 | 2019 | |
| Exeltis, USA INC. | $34.83 | 2019 | |
| Lupin INC. | $31.88 | 2019 | |
| Avion Pharmaceuticals | $29.34 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $25.14 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $24.47 | 2024 | Paragard T 380a |
| Pharmacosmos Therapeutics INC. | $18.43 | 2025 | Monoferric |
| Biogen, INC. | $18.18 | 2025 | Zurzuvae |
| Dermira, INC. | $15.82 | 2019 | |
| Merck Sharp & Dohme LLC | $14.84 | 2019 | |
| Roche Diagnostics Corporation | $14.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.